APO Research
Talk to an analyst

APO RESEARCH · REPORT

Transdermal Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Transdermal Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025196 pages

Choose your research edition.

Industry ResearchTransdermal Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Transdermal Drug Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Transdermal Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transdermal Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Transdermal Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Transdermal Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Transdermal Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Transdermal Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Transdermal Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Transdermal Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Transdermal Drug include Johnson & Johnson, Novartis, Mylan, GSK, Beijing Tide Pharmaceutical, Bayer, UCB Pharma, Teva Pharmaceutical and Nitto Denko, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Transdermal Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Transdermal Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Transdermal Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Transdermal Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Transdermal Drug Segment by Company

Johnson & Johnson

Novartis

Mylan

GSK

Beijing Tide Pharmaceutical

Bayer

UCB Pharma

Teva Pharmaceutical

Nitto Denko

Mundipharma

Luye Pharma Group

IBSA Group

Hisamitsu Pharmaceutical

Grünenthal

Dr Reddy’s Laboratories

Chattem

Transdermal Drug Segment by Type

Methyl Salicylate-based Patch

Diclofenac Patch

Nicotine Transdermal Patch

Lidocaine Patch

Rivastigmine Transdermal Patch

Fentanyl Transdermal Patch

Others

Transdermal Drug Segment by Application

Rx Channel

OTC Channel

Transdermal Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transdermal Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Transdermal Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Transdermal Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Transdermal Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Transdermal Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Transdermal Drug Industry Trends Table 2. Transdermal Drug Industry Drivers Table 3. Transdermal Drug Industry Opportunities and Challenges Table 4. Transdermal Drug Industry Restraints Table 5. Global Transdermal Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Transdermal Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Transdermal Drug Sales by Manufacturers (M Pcs) & (2021-2026) Table 8. Global Transdermal Drug Sales Market Share by Manufacturers Table 9. Global Transdermal Drug Average Sales Price (US$/Pcs) of Manufacturers (2021-2026) Table 10. Global Transdermal Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Transdermal Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Transdermal Drug Manufacturers, Product Type & Application Table 13. Global Transdermal Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Transdermal Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Methyl Salicylate-based Patch Table 17. Major Manufacturers of Diclofenac Patch Table 18. Major Manufacturers of Nicotine Transdermal Patch Table 19. Major Manufacturers of Lidocaine Patch Table 20. Major Manufacturers of Rivastigmine Transdermal Patch Table 21. Major Manufacturers of Fentanyl Transdermal Patch Table 22. Major Manufacturers of Others Table 23. Global Transdermal Drug Sales by Type 2021 VS 2025 VS 2032 (M Pcs) Table 24. Global Transdermal Drug Sales by Type (2021-2026) & (M Pcs) Table 25. Global Transdermal Drug Sales by Type (2027-2032) & (M Pcs) Table 26. Global Transdermal Drug Sales Market Share by Type (2021-2026) Table 27. Global Transdermal Drug Sales Market Share by Type (2027-2032) Table 28. Global Transdermal Drug Revenue by Type 2021 VS 2025 VS 2032 (M Pcs) Table 29. Global Transdermal Drug Revenue by Type (2021-2026) & (M Pcs) Table 30. Global Transdermal Drug Revenue by Type (2027-2032) & (M Pcs) Table 31. Global Transdermal Drug Revenue Market Share by Type (2021-2026) Table 32. Global Transdermal Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Rx Channel Table 34. Major Manufacturers of OTC Channel Table 35. Global Transdermal Drug Sales by Application 2021 VS 2025 VS 2032 (M Pcs) Table 36. Global Transdermal Drug Sales by Application (2021-2026) & (M Pcs) Table 37. Global Transdermal Drug Sales by Application (2027-2032) & (M Pcs) Table 38. Global Transdermal Drug Sales Market Share by Application (2021-2026) Table 39. Global Transdermal Drug Sales Market Share by Application (2027-2032) Table 40. Global Transdermal Drug Revenue by Application 2021 VS 2025 VS 2032 (M Pcs) Table 41. Global Transdermal Drug Revenue by Application (2021-2026) & (M Pcs) Table 42. Global Transdermal Drug Revenue by Application (2027-2032) & (M Pcs) Table 43. Global Transdermal Drug Revenue Market Share by Application (2021-2026) Table 44. Global Transdermal Drug Revenue Market Share by Application (2027-2032) Table 45. Global Transdermal Drug Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Table 46. Global Transdermal Drug Sales by Region (2021-2026) & (M Pcs) Table 47. Global Transdermal Drug Sales Market Share by Region (2021-2026) Table 48. Global Transdermal Drug Sales Forecasted by Region (2027-2032) & (M Pcs) Table 49. Global Transdermal Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Transdermal Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 51. North America Transdermal Drug Sales by Country (2021-2026) & (M Pcs) Table 52. North America Transdermal Drug Sales by Country (2027-2032) & (M Pcs) Table 53. Europe Transdermal Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 54. Europe Transdermal Drug Sales by Country (2021-2026) & (M Pcs) Table 55. Europe Transdermal Drug Sales by Country (2027-2032) & (M Pcs) Table 56. Asia Pacific Transdermal Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 57. Asia Pacific Transdermal Drug Sales by Country (2021-2026) & (M Pcs) Table 58. Asia Pacific Transdermal Drug Sales by Country (2027-2032) & (M Pcs) Table 59. South America, Middle East and Africa Transdermal Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 60. South America, Middle East and Africa Transdermal Drug Sales by Country (2021-2026) & (M Pcs) Table 61. South America, Middle East and Africa Transdermal Drug Sales by Country (2027-2032) & (M Pcs) Table 62. Global Transdermal Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Transdermal Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Transdermal Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Transdermal Drug Revenue Market Share by Region (2021-2026) Table 66. Global Transdermal Drug Revenue Market Share by Region (2027-2032) Table 67. Johnson & Johnson Company Information Table 68. Johnson & Johnson Business Overview Table 69. Johnson & Johnson Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Johnson & Johnson Transdermal Drug Product Portfolio Table 71. Johnson & Johnson Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Novartis Transdermal Drug Product Portfolio Table 76. Novartis Recent Development Table 77. Mylan Company Information Table 78. Mylan Business Overview Table 79. Mylan Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Mylan Transdermal Drug Product Portfolio Table 81. Mylan Recent Development Table 82. GSK Company Information Table 83. GSK Business Overview Table 84. GSK Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. GSK Transdermal Drug Product Portfolio Table 86. GSK Recent Development Table 87. Beijing Tide Pharmaceutical Company Information Table 88. Beijing Tide Pharmaceutical Business Overview Table 89. Beijing Tide Pharmaceutical Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Beijing Tide Pharmaceutical Transdermal Drug Product Portfolio Table 91. Beijing Tide Pharmaceutical Recent Development Table 92. Bayer Company Information Table 93. Bayer Business Overview Table 94. Bayer Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Bayer Transdermal Drug Product Portfolio Table 96. Bayer Recent Development Table 97. UCB Pharma Company Information Table 98. UCB Pharma Business Overview Table 99. UCB Pharma Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. UCB Pharma Transdermal Drug Product Portfolio Table 101. UCB Pharma Recent Development Table 102. Teva Pharmaceutical Company Information Table 103. Teva Pharmaceutical Business Overview Table 104. Teva Pharmaceutical Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Teva Pharmaceutical Transdermal Drug Product Portfolio Table 106. Teva Pharmaceutical Recent Development Table 107. Nitto Denko Company Information Table 108. Nitto Denko Business Overview Table 109. Nitto Denko Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Nitto Denko Transdermal Drug Product Portfolio Table 111. Nitto Denko Recent Development Table 112. Mundipharma Company Information Table 113. Mundipharma Business Overview Table 114. Mundipharma Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Mundipharma Transdermal Drug Product Portfolio Table 116. Mundipharma Recent Development Table 117. Luye Pharma Group Company Information Table 118. Luye Pharma Group Business Overview Table 119. Luye Pharma Group Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Luye Pharma Group Transdermal Drug Product Portfolio Table 121. Luye Pharma Group Recent Development Table 122. IBSA Group Company Information Table 123. IBSA Group Business Overview Table 124. IBSA Group Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. IBSA Group Transdermal Drug Product Portfolio Table 126. IBSA Group Recent Development Table 127. Hisamitsu Pharmaceutical Company Information Table 128. Hisamitsu Pharmaceutical Business Overview Table 129. Hisamitsu Pharmaceutical Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Hisamitsu Pharmaceutical Transdermal Drug Product Portfolio Table 131. Hisamitsu Pharmaceutical Recent Development Table 132. Grünenthal Company Information Table 133. Grünenthal Business Overview Table 134. Grünenthal Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Grünenthal Transdermal Drug Product Portfolio Table 136. Grünenthal Recent Development Table 137. Dr Reddy’s Laboratories Company Information Table 138. Dr Reddy’s Laboratories Business Overview Table 139. Dr Reddy’s Laboratories Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Dr Reddy’s Laboratories Transdermal Drug Product Portfolio Table 141. Dr Reddy’s Laboratories Recent Development Table 142. Chattem Company Information Table 143. Chattem Business Overview Table 144. Chattem Transdermal Drug Sales (M Pcs), Price (US$/Pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Chattem Transdermal Drug Product Portfolio Table 146. Chattem Recent Development Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Transdermal Drug Distributors List Table 150. Transdermal Drug Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Transdermal Drug Product Image Figure 2. Global Transdermal Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transdermal Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Transdermal Drug Sales (2021-2032) & (M Pcs) Figure 5. Global Transdermal Drug Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Top 5 and 10 Transdermal Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Methyl Salicylate-based Patch Image Figure 9. Diclofenac Patch Image Figure 10. Nicotine Transdermal Patch Image Figure 11. Lidocaine Patch Image Figure 12. Rivastigmine Transdermal Patch Image Figure 13. Fentanyl Transdermal Patch Image Figure 14. Others Image Figure 15. Global Transdermal Drug Sales by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 16. Global Transdermal Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Transdermal Drug Sales Market Share by Type (2021-2032) Figure 18. Global Transdermal Drug Revenue by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 19. Global Transdermal Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Transdermal Drug Revenue Market Share by Type (2021-2032) Figure 21. Rx Channel Image Figure 22. OTC Channel Image Figure 23. Global Transdermal Drug Sales by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 24. Global Transdermal Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Transdermal Drug Sales Market Share by Application (2021-2032) Figure 26. Global Transdermal Drug Revenue by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 27. Global Transdermal Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Transdermal Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 30. North America Transdermal Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 32. Canada Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 33. Mexico Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 34. Europe Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 35. Europe Transdermal Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 37. France Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 38. U.K. Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 39. Italy Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 40. Netherlands Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 41. Asia Pacific Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 42. Asia Pacific Transdermal Drug Sales Market Share by Country (2021-2032) Figure 43. China Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 44. Japan Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 45. South Korea Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 46. Southeast Asia Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 47. India Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 48. Australia Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 49. South America, Middle East and Africa Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 50. South America, Middle East and Africa Transdermal Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 52. South Africa Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 53. Saudi Arabia Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 54. Turkey Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 55. Argentina Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 56. UAE Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 57. Egypt Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 58. Chile Transdermal Drug Sales and Growth Rate (2021-2032) & (M Pcs) Figure 59. Global Transdermal Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Transdermal Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Transdermal Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Transdermal Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Transdermal Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Transdermal Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Transdermal Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Transdermal Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Transdermal Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Transdermal Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Transdermal Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Transdermal Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Methyl Salicylate-based Patch
  • Diclofenac Patch
  • Nicotine Transdermal Patch
  • Lidocaine Patch
  • Rivastigmine Transdermal Patch
  • Fentanyl Transdermal Patch
  • Others
Applications
  • Rx Channel
  • OTC Channel
Companies covered
  • Johnson & Johnson
  • Novartis
  • Mylan
  • GSK
  • Beijing Tide Pharmaceutical
  • Bayer
  • UCB Pharma
  • Teva Pharmaceutical
  • Nitto Denko
  • Mundipharma
  • Luye Pharma Group
  • IBSA Group
  • Hisamitsu Pharmaceutical
  • Grünenthal
  • Dr Reddy’s Laboratories
  • Chattem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Transdermal Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Transdermal Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Transdermal Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Transdermal Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Transdermal Drug Market Dynamics
  1. 2.1 Transdermal Drug Industry Trends
  2. 2.2 Transdermal Drug Industry Drivers
  3. 2.3 Transdermal Drug Industry Opportunities and Challenges
  4. 2.4 Transdermal Drug Industry Restraints
3 Transdermal Drug Market by Manufacturers
  1. 3.1 Global Transdermal Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Transdermal Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Transdermal Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Transdermal Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Transdermal Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Transdermal Drug Manufacturers, Product Type & Application
  7. 3.7 Global Transdermal Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Transdermal Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Transdermal Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Transdermal Drug Tier 1, Tier 2, and Tier 3
4 Transdermal Drug Market by Type
  1. 4.1 Transdermal Drug Type Introduction
  2. 4.1.1 Methyl Salicylate-based Patch
  3. 4.1.2 Diclofenac Patch
  4. 4.1.3 Nicotine Transdermal Patch
  5. 4.1.4 Lidocaine Patch
  6. 4.1.5 Rivastigmine Transdermal Patch
  7. 4.1.6 Fentanyl Transdermal Patch
  8. 4.1.7 Others
  9. 4.2 Global Transdermal Drug Sales by Type
  10. 4.2.1 Global Transdermal Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Transdermal Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Transdermal Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Transdermal Drug Revenue by Type
  14. 4.3.1 Global Transdermal Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Transdermal Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Transdermal Drug Revenue Market Share by Type (2021-2032)
5 Transdermal Drug Market by Application
  1. 5.1 Transdermal Drug Application Introduction
  2. 5.1.1 Rx Channel
  3. 5.1.2 OTC Channel
  4. 5.2 Global Transdermal Drug Sales by Application
  5. 5.2.1 Global Transdermal Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Transdermal Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Transdermal Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Transdermal Drug Revenue by Application
  9. 5.3.1 Global Transdermal Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Transdermal Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Transdermal Drug Revenue Market Share by Application (2021-2032)
6 Global Transdermal Drug Sales by Region
  1. 6.1 Global Transdermal Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Transdermal Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Transdermal Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Transdermal Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Transdermal Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Transdermal Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Transdermal Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Transdermal Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Transdermal Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Transdermal Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Transdermal Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Transdermal Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Transdermal Drug Revenue by Region
  1. 7.1 Global Transdermal Drug Revenue by Region
  2. 7.1.1 Global Transdermal Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Transdermal Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Transdermal Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Transdermal Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Transdermal Drug Revenue (2021-2032)
  8. 7.2.2 North America Transdermal Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Transdermal Drug Revenue (2021-2032)
  11. 7.3.2 Europe Transdermal Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Transdermal Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Transdermal Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Transdermal Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Transdermal Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Transdermal Drug Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Transdermal Drug Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Transdermal Drug Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Transdermal Drug Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Beijing Tide Pharmaceutical
  26. 8.5.1 Beijing Tide Pharmaceutical Company Information
  27. 8.5.2 Beijing Tide Pharmaceutical Business Overview
  28. 8.5.3 Beijing Tide Pharmaceutical Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beijing Tide Pharmaceutical Transdermal Drug Product Portfolio
  30. 8.5.5 Beijing Tide Pharmaceutical Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Transdermal Drug Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 UCB Pharma
  38. 8.7.1 UCB Pharma Company Information
  39. 8.7.2 UCB Pharma Business Overview
  40. 8.7.3 UCB Pharma Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 UCB Pharma Transdermal Drug Product Portfolio
  42. 8.7.5 UCB Pharma Recent Developments
  43. 8.8 Teva Pharmaceutical
  44. 8.8.1 Teva Pharmaceutical Company Information
  45. 8.8.2 Teva Pharmaceutical Business Overview
  46. 8.8.3 Teva Pharmaceutical Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva Pharmaceutical Transdermal Drug Product Portfolio
  48. 8.8.5 Teva Pharmaceutical Recent Developments
  49. 8.9 Nitto Denko
  50. 8.9.1 Nitto Denko Company Information
  51. 8.9.2 Nitto Denko Business Overview
  52. 8.9.3 Nitto Denko Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nitto Denko Transdermal Drug Product Portfolio
  54. 8.9.5 Nitto Denko Recent Developments
  55. 8.10 Mundipharma
  56. 8.10.1 Mundipharma Company Information
  57. 8.10.2 Mundipharma Business Overview
  58. 8.10.3 Mundipharma Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mundipharma Transdermal Drug Product Portfolio
  60. 8.10.5 Mundipharma Recent Developments
  61. 8.11 Luye Pharma Group
  62. 8.11.1 Luye Pharma Group Company Information
  63. 8.11.2 Luye Pharma Group Business Overview
  64. 8.11.3 Luye Pharma Group Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Luye Pharma Group Transdermal Drug Product Portfolio
  66. 8.11.5 Luye Pharma Group Recent Developments
  67. 8.12 IBSA Group
  68. 8.12.1 IBSA Group Company Information
  69. 8.12.2 IBSA Group Business Overview
  70. 8.12.3 IBSA Group Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 IBSA Group Transdermal Drug Product Portfolio
  72. 8.12.5 IBSA Group Recent Developments
  73. 8.13 Hisamitsu Pharmaceutical
  74. 8.13.1 Hisamitsu Pharmaceutical Company Information
  75. 8.13.2 Hisamitsu Pharmaceutical Business Overview
  76. 8.13.3 Hisamitsu Pharmaceutical Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hisamitsu Pharmaceutical Transdermal Drug Product Portfolio
  78. 8.13.5 Hisamitsu Pharmaceutical Recent Developments
  79. 8.14 Grünenthal
  80. 8.14.1 Grünenthal Company Information
  81. 8.14.2 Grünenthal Business Overview
  82. 8.14.3 Grünenthal Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Grünenthal Transdermal Drug Product Portfolio
  84. 8.14.5 Grünenthal Recent Developments
  85. 8.15 Dr Reddy’s Laboratories
  86. 8.15.1 Dr Reddy’s Laboratories Company Information
  87. 8.15.2 Dr Reddy’s Laboratories Business Overview
  88. 8.15.3 Dr Reddy’s Laboratories Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dr Reddy’s Laboratories Transdermal Drug Product Portfolio
  90. 8.15.5 Dr Reddy’s Laboratories Recent Developments
  91. 8.16 Chattem
  92. 8.16.1 Chattem Company Information
  93. 8.16.2 Chattem Business Overview
  94. 8.16.3 Chattem Transdermal Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Chattem Transdermal Drug Product Portfolio
  96. 8.16.5 Chattem Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Transdermal Drug Value Chain Analysis
  2. 9.1.1 Transdermal Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Transdermal Drug Production Mode & Process
  6. 9.2 Transdermal Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Transdermal Drug Distributors
  9. 9.2.3 Transdermal Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst